MyFinsight
Home
Blog
About
Contact
Maturities of short-term
investments
$99,251K
Net cash provided by
investing activities
$57,052K
Effect of exchange
rates on cash
$448K
Canceled cashflow
$42,199K
Net increase
(decrease) in cash, cash...
$7,915K
Canceled cashflow
$49,585K
Purchases of short-term
investments
$42,199K
Stock-based compensation
expense
$23,099K
Non-cash interest
expense
$4,577K
Foreign currency (gain)
loss
-$1,791K
Other long-term
assets, net
-$435K
Change in fair value of
embedded derivative...
$330K
Depreciation and
amortization
$252K
Other non-cash items
-$178K
Non-cash rent expense
$113K
Proceeds from the
exercise of stock options
$6,095K
Proceeds from issuance of
common stock from espp
$1,251K
Net cash used in
operating activities
-$44,185K
Net cash provided by
financing activities
-$5,400K
Canceled cashflow
$30,775K
Canceled cashflow
$7,346K
Total revenue, net
$60,112K
Net loss
-$55,639K
Tax withholding on
vesting of restricted...
$8,458K
Canceled cashflow
$60,112K
Accounts receivable
$8,110K
Accounts payable,
accrued expenses and...
-$5,618K
Inventory
$3,086K
Non-cash accretion &
amortization of short-term...
-$1,436K
Prepaid expenses and
other current assets
$487K
Deferred revenue
-$145K
Repayment of deferred
royalty obligation
$4,288K
Global headcount
expense
$58,653K
Commercial & medical
affairs
$20,264K
Preclinical, clinical and
development expense
$18,511K
Corporate, general &
administrative
$7,888K
Cost of sales
$7,157K
Other income
(expense), net
-$1,704K
Interest income
(expense), net
$1,029K
Income taxes
$545K
Cost of sales
$7,157K
Back
Back
Cash Flow
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)
source: myfinsight.com